Cerepeut Study in Neuron Identifies Mitochondrial Mechanism Driving Tau-Related Neurodegeneration and Highlights CP-235 as Potential Therapy
Cerepeut, Inc., a biotechnology company focused on developing mitochondrial therapeutics for neurodegenerative diseases, has announced the publication of new research in Neuron that identifies a previously unrecognized mechanism linking tau pathology, mitochondrial dysfunction, brain aging, and neurodegeneration. The study also introduces CP-235, Cerepeut’s lead drug candidate, as a potential therapeutic approach designed to interrupt this disease-driving mechanism at its source.
The findings provide new insight into how pathological tau may contribute to the progression of Alzheimer’s disease and other tauopathies. While tau has long been recognized as a major pathological feature of Alzheimer’s disease because of its ability to accumulate into toxic intracellular tangles, the research indicates that tau has another important role within mitochondria, the cellular structures responsible for producing energy.
According to the study, phosphorylated tau, or pTau, can directly interact with mitochondrial machinery involved in a process known as reverse electron transport (RET). Under normal physiological conditions, RET is carefully regulated. However, in aging and neurodegenerative disease, excessive activation of RET may create a harmful feedback loop in which mitochondrial dysfunction promotes additional tau phosphorylation, which in turn further activates RET.
Cerepeut believes this newly identified mechanism could provide an important new target for treating diseases driven by abnormal tau biology.
Identifying a Self-Perpetuating Disease Cycle
Tau is a protein that normally contributes to the structure and function of neurons. In Alzheimer’s disease and several other neurodegenerative conditions, however, tau can become abnormally phosphorylated and undergo changes that promote its accumulation inside neurons.
These pathological forms of tau are associated with neuronal dysfunction and eventual cell death.
The new research suggests that the role of pTau may extend beyond the formation of intracellular aggregates. Researchers found that pTau can directly engage with Complex I, a component of the mitochondrial electron transport chain, and influence RET.
Reverse electron transport is a mitochondrial process that can generate reactive oxygen species under particular metabolic conditions. Although controlled RET activity has physiological roles, excessive activation can contribute to cellular stress.
The Cerepeut-led research proposes that pathological tau can disrupt this balance.
When pTau excessively activates RET, the resulting mitochondrial signaling promotes additional tau phosphorylation. The increase in pTau then further stimulates RET, creating a cycle that can perpetuate neuronal damage.
This mechanism could help explain how tau pathology becomes progressively worse rather than remaining static within affected neurons.
Bingwei Lu, Ph.D., a co-founder of Cerepeut and researcher at Stanford University, described the process as a self-sustaining mechanism that can drive neurodegeneration.
The research team’s focus is therefore not solely on removing tau once it has accumulated. Instead, the proposed strategy is to interfere with the biological process that helps generate and sustain pathological tau.
CP-235 Designed to Interrupt the Cycle
Cerepeut researchers investigated whether blocking RET could disrupt the pTau-driven feedback mechanism.
The company’s lead compound, CP-235, was evaluated for its ability to inhibit RET and determine whether suppressing the mitochondrial pathway could reduce pathological tau.
In the study, the compound is also referred to as CPT.
Researchers reported that inhibiting RET with CP-235 reduced levels of phosphorylated tau while leaving total tau levels unaffected. This distinction is potentially important because tau itself performs normal biological functions, meaning that selectively reducing pathological phosphorylation could represent a different therapeutic strategy from broadly eliminating the protein.
The effects of CP-235 were evaluated across multiple experimental systems, including fruit fly models, rTg4510 mice, and human induced pluripotent stem cell-derived neurons.
Across these models, researchers reported evidence that the compound could interrupt the pTau-RET feedback loop.
Improvements in Cognitive and Neurological Measures
The preclinical research also evaluated the broader consequences of RET inhibition.
Treatment with CP-235 was reported to rescue cognitive deficits, reduce brain atrophy, protect neurons from degeneration, and decrease neuroinflammation.
These findings are particularly relevant because neurodegenerative diseases such as Alzheimer’s involve multiple interconnected pathological processes. Abnormal protein accumulation is accompanied by neuronal dysfunction, inflammation, mitochondrial abnormalities, and progressive loss of brain tissue.
A treatment strategy capable of influencing several of these processes through a common upstream mechanism could potentially offer advantages over approaches that address only one downstream manifestation of disease.
However, the reported findings are preclinical, and additional research will be required to determine whether the biological effects observed in laboratory and animal models translate into meaningful clinical benefits in humans.
Evidence from Human Alzheimer’s Brain Tissue
An important component of the research was the investigation of RET activity in human disease.
The research team identified evidence of excessive RET signaling in human Alzheimer’s disease brain tissue, as well as in animal models of tauopathy.
The presence of the same biological signal in human patient tissue strengthens the potential relevance of the mechanism beyond experimental models.
This finding supports the researchers’ hypothesis that abnormal RET activation is not simply an artifact of a particular laboratory model but may represent a feature of human neurodegenerative disease.
Human tissue findings can be especially valuable during early drug development because they can help establish a biological connection between a proposed therapeutic target and the disease process that occurs in patients.
Potential Application Across Multiple Tauopathies
Although Alzheimer’s disease is one of the best-known tauopathies, abnormal tau biology is also associated with several other neurodegenerative disorders.
Cerepeut believes that the pTau-RET mechanism could have implications for conditions including progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and corticobasal degeneration (CBD).
These diseases differ in their clinical manifestations, but abnormal tau accumulation and related neuronal dysfunction play important roles in several of them.
A common therapeutic mechanism affecting pathological tau biology could therefore potentially be relevant across multiple diseases.
The company is advancing its lead program with the goal of eventually evaluating CP-235 in clinical development for neurodegenerative diseases associated with tau pathology.
Mitochondria as a Therapeutic Target
The study also reinforces growing interest in mitochondria as potential targets for neurodegenerative disease therapies.
Neurons have exceptionally high energy requirements and depend heavily on healthy mitochondrial function. Disruptions in energy production, oxidative stress, and mitochondrial signaling can contribute to neuronal dysfunction and vulnerability.
Historically, much Alzheimer’s research has focused on pathological proteins such as amyloid-beta and tau. The Cerepeut research adds to efforts to understand how these pathological proteins interact with fundamental cellular processes such as mitochondrial energy metabolism.
By identifying a direct relationship between tau and mitochondrial RET, the study provides a potential connection between protein pathology and cellular energy dysfunction.
Cerepeut’s therapeutic strategy is based on the idea that targeting this connection could potentially influence disease progression rather than simply treating symptoms or attempting to remove pathological proteins after extensive damage has occurred.
Cross-Institutional Research Collaboration
The study was conducted through a collaboration involving Cerepeut and researchers from several leading academic institutions.
The research was led by Bingwei Lu, Ph.D., of Stanford University, and Su Guo, Ph.D., of the University of California, San Francisco (UCSF), both of whom are co-founders of Cerepeut.
The collaboration included researchers from Stanford University School of Medicine’s Department of Pathology as well as multiple UCSF departments and centers.
These included the Memory and Aging Center, Department of Neurology, Department of Pathology, Department of Bioengineering and Therapeutic Sciences, and the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research.
The combination of academic neuroscience, mitochondrial biology, disease modeling, and drug discovery contributed to the study’s multidisciplinary approach.
Safety and Drug Development Potential
According to Cerepeut, CP-235 was well tolerated across the preclinical models evaluated in the study.
Hua Tu, Ph.D., President and CEO of Cerepeut, said the findings provide both a potential therapeutic candidate and a biological target that could address pathological tau signaling through a different mechanism.
The company views the tolerability findings as supportive of continued development, although safety and efficacy in humans will ultimately need to be established through appropriately designed clinical trials.
Moving from animal and cellular models into human clinical studies represents a significant step in the development process. Future studies will need to determine the appropriate dose, pharmacological behavior, safety profile, biological activity, and potential clinical benefit of CP-235 in patients.
A New Direction for Tau-Focused Therapies
The findings published in Neuron could contribute to a broader understanding of how Alzheimer’s disease and related tauopathies progress.
Rather than viewing tau pathology exclusively as a consequence of abnormal protein accumulation, the study proposes that pathological tau can actively interfere with mitochondrial processes, creating a feedback mechanism that accelerates further tau modification and neuronal damage.
Breaking this feedback loop could represent a fundamentally different therapeutic approach.
The study’s results across fruit flies, mice, human stem cell-derived neurons, and human Alzheimer’s brain tissue provide multiple lines of preclinical evidence supporting further investigation of the mechanism.
Cerepeut’s development strategy is now focused on translating these findings into potential clinical applications. If subsequent studies confirm that RET inhibition can safely reduce pathological tau activity and improve disease-related outcomes in humans, CP-235 could potentially become part of a new generation of therapies targeting the biological mechanisms that connect mitochondrial dysfunction with neurodegeneration.
For patients with Alzheimer’s disease, PSP, FTD, CBD, and other tau-related disorders, the need for disease-modifying treatments remains substantial. The Cerepeut research offers a new perspective on that challenge by identifying mitochondrial RET as a potential driver of pathological tau biology.
The company believes that targeting the pTau-RET feedback loop could ultimately provide an opportunity to intervene earlier in the disease process and potentially alter the trajectory of neurodegeneration. While the findings remain at the preclinical stage, the publication in Neuron represents an important research milestone for Cerepeut and provides a scientific foundation for advancing CP-235 toward clinical development.
About Cerepeut
Cerepeut is a biotechnology company restoring mitochondrial resilience in neurodegenerative disease and age-related decline. Its first-in-class small molecule, CP-235, targets pathological mitochondrial RET to break the pTau-RET feedback loop, reduce oxidative stress, and preserve neuronal function. Cerepeut’s lead program is advancing toward clinical development for tau-related neurodegenerative diseases.